UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources
In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).
In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”
Corcept Therapeutics closed on Friday at $4.08.
Latest Ratings for CORT
|Apr 2015||FBR Capital||Initiates Coverage on||Outperform|
|Mar 2015||Piper Jaffray||Upgrades||Neutral||Overweight|
|Apr 2014||Brinson Patrick||Initiates Coverage on||Market Outperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.